HBIO CIK: 1123494

Harvard Bioscience Inc.

  • United States
  • Healthcare
  • MedTech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
61.6
FY22:
51.1
FY23:
49.0
FY24:
45.1
FY25:
48.2
(positive)
Change from FY21 to FY25
millions USD
FY21:
101
FY22:
94.2
FY23:
88.3
FY24:
81.5
FY25:
31.8
Total assets
Change from FY21 to FY25
millions USD
FY21:
162
FY22:
145
FY23:
137
FY24:
127
FY25:
80.1

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
25.3
FY22:
23.2
FY23:
26.5
FY24:
55.0
FY25:
22.0
(negative)
Change from FY21 to FY25
millions USD
FY21:
53.6
FY22:
49.9
FY23:
37.8
FY24:
8.35
FY25:
44.4
(positive)
Change from FY21 to FY25
millions USD
FY21:
83.4
FY22:
72.2
FY23:
73.1
FY24:
63.3
FY25:
13.7
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
162
FY22:
145
FY23:
137
FY24:
127
FY25:
80.1

All amounts in millions USD Data source:SEC EDGAR